-
1.发明公开CELL USABLE IN SERUM-FREE CULTURE AND SUSPENSION CULTURE AND PROCESS FOR PRODUCING VIRUS FOR VACCINE BY USING THE CELL 有权在病毒生产无血清培养合适的细胞培养物悬浮液和方法作为疫苗使用细胞
公开(公告)号：EP1260581A1
公开(公告)日：2002-11-27
申请号：EP01908228.8
申请日：2001-03-02
IPC分类号： C12N5/06 , C12N7/00 , C07K14/005 , A61K39/12
CPC分类号： C12N5/0686 , A61K39/12 , C12N7/00 , C12N2500/92 , C12N2510/02 , C12N2710/16634 , C12N2760/16134 , C12N2760/16234 , C12N2760/18434 , C12N2760/18734 , C12N2770/36234
摘要： A novel MDCK-derived cell line (B-702) is provided that can be grown in the absence of fetal calf serum and in suspension culture for allowing a tank culture on the production scale and needs no carrier in suspension culture, as well as a process for producing virus for vaccine by using said cell line in a low-cost, highly safe and stable manner.
摘要翻译： 本发明提供一种新颖的MDCK衍生细胞系（B-702）也可以在不存在胎牛血清和在悬浮培养物中生长，以允许在生产规模的罐培养，无需载体在悬浮培养中，以及一个 用于通过使用所述细胞系在一个低成本，高安全性和稳定的方式制备用于疫苗病毒的过程。
-
公开(公告)号：EP0690132A1
公开(公告)日：1996-01-03
申请号：EP94909286.0
申请日：1994-03-09
发明人： EDA, Yasuyuki , MAEDA, Hiroaki , MAKIZUMI, Keiichi , SHIOSAKI, Kouichi , OSATOMI, Kiyoshi , KIMACHI, Kazuhiko , HIGUCHI, Hirofumi , TOKIYOSHI, Sachio
CPC分类号： C07K16/1063 , A61K38/00 , C07K2317/24
摘要： The invention provides a clinically useful monoclonal antibody which can recognize the conserved region of the V3-PND region of a glycoprotein antigen (gp120) having a molecular weight of about 120,000 Da and contained in the coat of a human immunodefiency virus (HIV) and which can neutralize a wide variety of HIV variants, or a fragment of the above antibody, and chimera and humanized antibodies derived from the above antibody. It is possible to prepare a monoclonal antibody having the activity of neutralizing various HIV variants by using as the immunogen several types of peptides having a PND tip region containing a GPGR sequence having a high conservability in the PND region of the gp120 of an HIV. It is possible to obtain a chimera antibody or an altered antibody having an anti-HIV neutralization activity effective for clinical application by transplanting a fragment of a gene coding for the variable region of the above monoclonal antibody or the complementarity-determining region of that region to a human antibody gene.
摘要翻译： 本发明提供临床有用的单克隆抗体，其可以识别分子量为约120,000Da且包含在人免疫缺陷病毒（HIV）的外壳中的糖蛋白抗原（gp120）的V3-PND区域的保守区域，并且其中 可以中和各种HIV变体，或上述抗体的片段，以及衍生自上述抗体的嵌合体和人源化抗体。 可以制备具有中和各种HIV变异体的活性的单克隆抗体，该单克隆抗体具有在HIV的gp120的PND区域中具有包含具有高保守性的GPGR序列的PND末端区域的几种类型的肽作为免疫原。 可以通过将编码上述单克隆抗体的可变区的基因的片段或该区域的互补决定区域移植到具有对临床应用有效的抗HIV中和活性的嵌合体抗体或改变的抗体 人抗体基因。
-
公开(公告)号：EP1595959A1
公开(公告)日：2005-11-16
申请号：EP04712210.6
申请日：2004-02-18
发明人： MURAKAMI, Toshio , HIGUCHI, Hirofumi , MAKIZUMI, Keiichi , MAEDA, Toshihiro , MIZOKAMI, Hiroshi
IPC分类号： C12Q1/68 , A61K39/395 , A61P31/18
CPC分类号： C07K16/00 , A61K2039/505 , C07K16/1063 , C07K2317/34
摘要： A method for enhancing efficacy of a monoclonal antibody preparation is provided wherein antigens from patients are tested for their reactivity with said antibody. In accordance with the method of the invention, an amino acid sequence of an expressed protein is deduced from a nucleotide sequence determined by isolation and analysis of a target molecule gene in biopsy from patients and is compared with the previously determined amino acid sequence recognized by said monoclonal antibody preparation to thereby assess fitness of patients for administration of said monoclonal antibody preparation.
摘要翻译： 提供worin抗原一种用于增强单克隆抗体制备物的功效的方法，从患者测试它们与所述抗体的反应性。 在符合本发明的方法中雅舞蹈，于氨基酸的过量表达的蛋白质的氨基酸序列是从患者通过在活检靶分子基因的分离和分析开采的核苷酸序列确定的推断，并且与由所述识别的以前确定的开采氨基酸序列相比 单克隆抗体的制备，从而评估患者对所述单克隆抗体制剂的给药健身。
-
4.发明授权CELL USABLE IN SERUM-FREE CULTURE AND SUSPENSION CULTURE AND PROCESS FOR PRODUCING VIRUS FOR VACCINE BY USING THE CELL 有权在病毒生产无血清培养合适的细胞培养物悬浮液和方法作为疫苗使用细胞
公开(公告)号：EP1260581B1
公开(公告)日：2010-07-07
申请号：EP01908228.8
申请日：2001-03-02
IPC分类号： C12N5/07 , C12N7/00 , C07K14/005 , A61K39/12
CPC分类号： C12N5/0686 , A61K39/12 , C12N7/00 , C12N2500/92 , C12N2510/02 , C12N2710/16634 , C12N2760/16134 , C12N2760/16234 , C12N2760/18434 , C12N2760/18734 , C12N2770/36234
摘要： A novel MDCK cell-induction line (B-702) which can be cultured without using fetal bovine serum, has been suspended to enable tank culture on the production scale and requires no support in the suspended state; and a process for economically, highly safely and stably producing a virus for a vaccine by using the above cell.
-
公开(公告)号：EP0690132B1
公开(公告)日：2003-12-17
申请号：EP94909286.0
申请日：1994-03-09
发明人： EDA, Yasuyuki , MAEDA, Hiroaki , MAKIZUMI, Keiichi , SHIOSAKI, Kouichi , OSATOMI, Kiyoshi , KIMACHI, Kazuhiko , HIGUCHI, Hirofumi , TOKIYOSHI, Sachio
CPC分类号： C07K16/1063 , A61K38/00 , C07K2317/24
摘要： The invention provides a clinically useful monoclonal antibody which can recognize the conserved region of the V3-PND region of a glycoprotein antigen (gp120) having a molecular weight of about 120,000 Da and contained in the coat of a human immunodefiency virus (HIV) and which can neutralize a wide variety of HIV variants, or a fragment of the above antibody, and chimera and humanized antibodies derived from the above antibody. It is possible to prepare a monoclonal antibody having the activity of neutralizing various HIV variants by using as the immunogen several types of peptides having a PND tip region containing a GPGR sequence having a high conservability in the PND region of the gp120 of an HIV. It is possible to obtain a chimera antibody or an altered antibody having an anti-HIV neutralization activity effective for clinical application by transplanting a fragment of a gene coding for the variable region of the above monoclonal antibody or the complementarity-determining region of that region to a human antibody gene.
-
-
-
-
搜索结果
5 条记录 (耗时 0.017 秒)
